The Fort Worth Press - Moderna Announces Updates on Pandemic Influenza Program

USD -
AED 3.672498
AFN 63.999702
ALL 82.464942
AMD 358.505756
ANG 1.790403
AOA 917.498647
ARS 1549.870021
AUD 1.484032
AWG 1.8025
AZN 1.696134
BAM 1.779156
BBD 2.017129
BDT 124.690139
BGN 1.77347
BHD 0.378157
BIF 3007.43672
BMD 1
BND 1.291033
BOB 11.682086
BRL 5.7845
BSD 1.001496
BTN 94.002656
BWP 14.018585
BYN 3.009424
BYR 19600
BZD 2.014218
CAD 1.43019
CDF 2317.999943
CHF 0.838915
CLF 0.025357
CLP 997.979904
CNY 6.66455
CNH 6.66546
COP 3317.23
CRC 446.292118
CUC 1
CUP 24.035623
CVE 100.306108
CZK 22.17145
DJF 178.348063
DKK 6.78993
DOP 60.867113
DZD 137.008028
EGP 53.678304
ERN 15
ETB 164.376481
EUR 0.90833
FJD 2.296799
FKP 0.758367
GBP 0.757835
GEL 2.594988
GGP 0.758367
GHS 11.732118
GIP 0.758367
GMD 73.501169
GNF 8873.120921
GTQ 7.654066
GYD 209.544342
HKD 7.846035
HNL 26.932961
HRK 6.831965
HTG 131.250142
HUF 330.815503
IDR 18233.75
ILS 3.248749
IMP 0.758367
INR 93.57705
IQD 1518.259596
IRR 1925253.9999
ISK 124.25976
JEP 0.758367
JMD 158.794125
JOD 0.708947
JPY 159.196501
KES 130.050152
KGS 87.449398
KHR 4106.5296
KMF 447.498309
KPW 900.00035
KRW 1338.809943
KWD 0.311439
KYD 0.834633
KZT 445.59873
LAK 22549.202436
LBP 89683.974965
LKR 333.298462
LRD 170.2507
LSL 16.970744
LTL 2.95274
LVL 0.60489
LYD 6.470746
MAD 9.982716
MDL 18.317444
MGA 4555.8128
MKD 55.91772
MMK 2099.8229
MNT 3605.49036
MOP 8.0932
MRU 40.667528
MUR 47.859839
MVR 15.410333
MWK 1736.583325
MXN 18.50519
MYR 4.091198
MZN 63.909632
NAD 16.970667
NGN 1346.080103
NIO 36.851561
NOK 9.64695
NPR 150.403886
NZD 1.81999
OMR 0.384499
PAB 1.001465
PEN 3.415402
PGK 4.572229
PHP 63.736022
PKR 276.920096
PLN 3.99624
PYG 6215.118421
QAR 3.660925
RON 4.854006
RSD 106.818972
RUB 82.598925
RWF 1479.507134
SAR 3.763042
SBD 8.098361
SCR 14.276828
SDG 601.518606
SEK 10.083204
SGD 1.288005
SHP 0.758581
SLE 23.049833
SLL 20969.503664
SOS 572.372042
SRD 37.4535
STD 20697.981008
STN 22.288025
SVC 8.762969
SYP 13002.000337
SZL 16.966036
THB 33.82499
TJS 9.228432
TMT 3.51
TND 3.027513
TOP 2.40776
TRY 50.417195
TTD 6.801694
TWD 32.962498
TZS 2651.997978
UAH 45.525197
UGX 4156.319079
UYU 40.6615
UZS 12027.818082
VES 914.603596
VND 25735
VUV 120.845902
WST 2.802705
XAF 595.82556
XAG 0.021012
XAU 0.0002579996
XCD 2.70255
XCG 1.8049
XDR 0.707052
XOF 595.82556
XPF 108.488699
YER 236.49594
ZAR 16.959115
ZMK 9001.1985
ZMW 20.506056
ZWL 321.999592
SSP 5946.953244
MXV 2.075993
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Moderna Announces Updates on Pandemic Influenza Program
Moderna Announces Updates on Pandemic Influenza Program

Moderna Announces Updates on Pandemic Influenza Program

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR).

Text size:

The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines. The agreement will also support the expansion of clinical studies for up to five additional subtypes of pandemic influenza.

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults aged 18 years and older. The study included vaccine candidates against H5 and H7 avian influenza viruses. Based on the positive preliminary data from the Phase 1/2 study, Moderna is preparing to advance mRNA-1018 into Phase 3.

The Company looks forward to sharing the Phase 1/2 results at an upcoming scientific meeting. This $590 million award has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the commitment of funding from BARDA to Moderna to support the development of mRNA-based pandemic influenza vaccines; and the advancement of Moderna's current candidates against H5 and H7 avian flu viruses. The forward- looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Chris Ridley
Global Head of Media Relations
+1 617-800-3651
[email protected]

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.



View the original press release on ACCESS Newswire

C.M.Harper--TFWP